Saturday, February 3, 2018 — 8:00 a.m. - 5:00 p.m. (local time)
This workshop is available to SLAS2018 registrants only and requires an additional registration fee of $399.00. Click here to register now.
This full-day workshop will cover a broad range of critical concepts underlying assay development for high throughput screening (HTS) and lead discovery projects. Many of the methodologies successfully implemented in such projects have been "tribal knowledge" within the pharmaceutical industry and not readily found in a classroom or the literature. This "tribal knowledge" has been developed for decades into detailed chapters within the AGM to facilitate reproducible assays that can identify the most promising compounds for development of molecular probes or clinical candidates for drug discovery and development. An increasing number of researchers are actively developing well validated assays for drug discovery that include phenotypic and biochemical assays for lead optimization. This workshop is designed to disseminate critical information about the implementation of robust assay methods and intended to benefit the entire drug discovery community. Many of the workshop instructors have 20-30 years of experience in the field of drug discovery.
The target audience is individuals involved in bioassay development for drug discovery and development. The AGM and this workshop will be a valuable resource for academic, industrial and government laboratory scientists who are planning or beginning to develop test methods for high or low throughput screening that are amenable to automation using appropriate statistical and operational concepts. The workshop will also be useful for early career researchers and experienced investigators who wish to learn about the latest assay concepts for HTS and lead optimization
The workshop will provide participants with a broad, practical perspective on assay development so that they can (1) improve research projects involving drug discovery, and know where to find further information (2) identify reagents, methods and instrumentation that are well suited to robust assays (3) be able to develop robust assays and counter assays for new targets. Additionally, participants will have the opportunity to seek practical advice about individual research challenges.
|8:00-8:45AM||Strategies for Assay Selection and for the Development of Robust Biochemical Assays
Nathan P. Coussens, Ph.D., NCATS/NIH
|8:50-9:35AM||Treating Cells as Reagents to Design Reproducible Screening Assays
Terry Riss, Ph.D., Promega Corporation
|10:00-10:45AM||Assay Interpretation: Studies in Mechanisms and Methods in Assay Interferences
Douglas Auld, Ph.D., Novartis Institutes for BioMedical Research
|10:55-11:15AM||Robust or Go Bust: An Introduction to the Assay Guidance Manual
G. Sitta Sittampalam, Ph.D., NCATS/NIH
|12:00-12:45PM||Biophysical Approaches to Small Molecule Discovery and Validation
Michelle Arkin, Ph.D., University of California, San Francisco
|12:55-1:40PM||In Vitro Toxicological Testing using a qHTS Platform
Menghang Xia, Ph.D., NCATS/NIH
|2:00-2:45PM||In Vitro Assessments of ADME Properties of Lead Compounds
Xin Xu, Ph.D., NCATS/NIH
|2:55-3:40PM||Basic Assay Statistics, Data Analysis and Rules of Thumb
Thomas D.Y. Chung, Ph.D., Mayo Clinic
|3:50-4:35PM||System suitability of in-vitro screening assays in drug discovery
V. Devanarayan, Ph.D., Charles River